Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Ritesh N. Kumar"'
Autor:
Alex Wong, Giada Sebastiani, Curtis Cooper, Réjean Thomas, Dan Smyth, Brian Conway, Gretty Deutsch, Hemant Shah, Ritesh N. Kumar, Ted Watson
Publikováno v:
Canadian liver journal. 4(4)
BACKGROUND: Development of robust treatment programs among core transmitters (CT) of hepatitis C virus (HCV) are needed, including strategies to address reinfection risk. The aim of this study was to describe the effectiveness of direct-acting antivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6505114eac448252432f8b5e7ecdef72
https://pubmed.ncbi.nlm.nih.gov/35989890
https://pubmed.ncbi.nlm.nih.gov/35989890
Autor:
Abdul-Badi Abou-Samra, Adeel A. Butt, Amy Puenpatom, Ritesh N. Kumar, Yanjie Ren, Jean-Marie Arduino
Publikováno v:
Liver International. 38:1411-1417
Background Newer direct acting antiviral agents against HCV (DAAs) are safe and efficacious in persons with chronic kidney disease (CKD). Whether approval of newer DAAs has resulted in more persons with CKD initiating HCV treatment remains unknown. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de22e8244870d394da025f5a043a49bd
https://doi.org/10.1111/liv.13672
https://doi.org/10.1111/liv.13672
Autor:
Abdul-Badi Abou-Samra, Y. Ren, Jean Marie Arduino, Ritesh N. Kumar, Adeel A. Butt, Amy Puenpatom
Publikováno v:
Alimentary pharmacologytherapeutics. 48(1)
Background Chronic kidney disease (CKD) was a relative contraindication to hepatitis C virus (HCV) treatment in the interferon/ribavirin era. Aim To determine the efficacy, tolerability and safety of sofosbuvir/ledipasvir (SOF/LDV) and paritaprevir/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355bd2e7cf5d6c2d6411a9fc96ee81c4
https://pubmed.ncbi.nlm.nih.gov/29998505
https://pubmed.ncbi.nlm.nih.gov/29998505
Autor:
Amy Puenpatom, Adeel A. Butt, Jean Marie Arduino, Ritesh N. Kumar, Yanjie Ren, Abdul-Badi Abou-Samra
Publikováno v:
Open Forum Infectious Diseases
Background Newer directing antiviral agents against HCV (DAAs) are safe and efficacious in persons with chronic kidney disease (CKD). Whether availability of these newer DAAs has resulted in more persons with CKD initiating HCV treatment remains unkn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c533080fc4d083c6eb640df21b8ea5de
http://europepmc.org/articles/PMC5632023
http://europepmc.org/articles/PMC5632023
Autor:
Y. Ren, Abdul-Badi Abou-Samra, Adeel A. Butt, Jean Marie Arduino, Ritesh N. Kumar, Amy Puenpatom, Mohamad Alkadi
Publikováno v:
Gastroenterology. 152:S1100-S1101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8815aa32135eb49dc13fdac5c06121ba
https://doi.org/10.1016/s0016-5085(17)33707-1
https://doi.org/10.1016/s0016-5085(17)33707-1
Autor:
Amy Puenpatom, Adeel A. Butt, Abdul-Badi Abou-Samra, Jean Marie Arduino, Y. Ren, Ritesh N. Kumar, Mohamad Alkadi
Publikováno v:
Journal of Hepatology. 66:S724-S725
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f11eb44b0c5c08777314b9925db12956
https://doi.org/10.1016/s0168-8278(17)31934-7
https://doi.org/10.1016/s0168-8278(17)31934-7
Autor:
Amy Puenpatom, Adeel A. Butt, Abdul-Badi Abou-Samra, Yanjie Ren, Ritesh N. Kumar, Jean Marie Arduino
Publikováno v:
Open Forum Infectious Diseases
Background Chronic kidney disease (CKD) was a relative contraindication to HCV treatment in the interferon/ribavirin era due to poor tolerability and lower efficacy. Our aim was to determine the effectiveness treatment completion, and safety of sofos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107bca42d2bf96138a053d5bc3833dbb
https://doi.org/10.1093/ofid/ofx163.376
https://doi.org/10.1093/ofid/ofx163.376
Publikováno v:
HIV Clinical Trials. 12:175-189
Compare the efficacy of 2 NRTIs combined with raltegravir (RAL), efavirenz (EFV), or protease inhibitors (PI) in the management of antiretroviral-naïve HIV adult patients.By means of a systematic literature view, 7 randomized controlled trials were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61353e1fd2558d0ecea178107bca00f2
https://doi.org/10.1310/hct1204-175
https://doi.org/10.1310/hct1204-175
Publikováno v:
Scandinavian Journal of Infectious Diseases. 43:504-514
To evaluate the cost-effectiveness of caspofungin versus liposomal amphotericin B (L-AmB) for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.With a decision-analytic model, the expected direct costs, life-yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c523f6bc61077e10d5660f4fcd23abda
https://doi.org/10.3109/00365548.2011.556145
https://doi.org/10.3109/00365548.2011.556145
Autor:
Nikolay Klimko, Ritesh N. Kumar, Sasisopin Kiertiburanakul, Tami Wisniewski, Michel Laverdière, Kliasova Ga, Rudolf Trenschel
Publikováno v:
Mycoses. 54:e148-e153
To evaluate caspofungin in high-risk invasive aspergillosis (IA) patient, a retrospective review of patient characteristics, antifungal therapies and clinical outcomes on hospitalised patients at sites in Russia, Canada, Germany, and Thailand was per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d846c8750ce3ae00b0b7cac384dfc025
https://doi.org/10.1111/j.1439-0507.2010.01861.x
https://doi.org/10.1111/j.1439-0507.2010.01861.x